Horizon Therapeutics PLC (HZNP) stock is higher by 170.25% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives HZNP stock a score of 84 out of a possible 100.
That rank is chiefly influenced by a long-term technical score of 91. HZNP's rank also includes a fundamental score of 81. In addition to the average rating from Wall Street analysts, HZNP stock has a mean target price of 105. This means analysts expect the stock to add 40.26% over the next 12 months. The short-term technical score for HZNP is 79.
What's Happening with HZNP Stock Today
Horizon Therapeutics PLC (HZNP) stock has fallen -4.58% while the S&P 500 is higher by 1.01% as of 2:18 PM on Tuesday, Oct 20. HZNP is lower by -$3.60 from the previous closing price of $78.46 on volume of 2,334,310 shares. Over the past year the S&P 500 has gained 15.13% while HZNP is higher by 170.25%. HZNP earned $2.45 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 30.61.
Click Here to get the full Stock Score Report on Horizon Therapeutics PLC (HZNP) Stock.
